<DOC>
	<DOCNO>NCT00246376</DOCNO>
	<brief_summary>This study evaluate efficacy diet exercise ( DE ) , without niacin fenofibrate , reduce cardiovascular risk patient HIV lipodystrophy dyslipidemia .</brief_summary>
	<brief_title>Diet , Exercise , Niacin , Fenofibrate Reduce Heart Disease Risk Factors Individuals With HIV Lipodystrophy Dyslipidemia</brief_title>
	<detailed_description>BACKGROUND : HIV lipodystrophy syndrome associate metabolic ( e.g. , dyslipidemia insulin resistance ) anthropomorphic ( e.g. , lipoatrophy central obesity ) abnormality . These defect likely predispose HIV patient highly active antiretroviral therapy ( HAART ) accelerate cardiovascular morbidity . Based study key mechanism alter lipid kinetics patient , evidence DE pattern patient HIV lipodystrophy inadequate manage cardiovascular risk factor , current recommendation treatment atherosclerosis insulin resistance , follow hypothesize : 1 ) intensive lifestyle intervention DE improve plasma lipid profile , decrease visceral fat mass , improve hormonal , metabolic , lipoprotein marker associate insulin resistance ; 2 ) add niacin , fenofibrate , combination two drug intensive lifestyle intervention result improvement cardiovascular risk profile . DESIGN NARRATIVE : This randomize , placebo-controlled study 200 hypertriglyceridemic HIV patient stable HAART treatment follow specific aim : 1 ) compare effect usual care , intensive DE , DE plus niacin , DE plus fenofibrate , DE plus niacin plus fenofibrate fasting plasma lipid concentration ( primary endpoint ) ; 2 ) compare effect five treatment protocol body fat distribution ; 3 ) compare effect five treatment protocol hormonal , lipoprotein , metabolic marker insulin resistance . The collaborative team expertise lipid lipoprotein metabolism , innovative effective diet modification program , intensive exercise program HIV patient , study antilipidemic antiretroviral agent . Therefore , study determine efficacy DE , without niacin fenofibrate , reduce cardiovascular risk patient HIV lipodystrophy dyslipidemia .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>HIV positive On stable HAART regimen least 6 month prior study entry Tcell count great 100 viral load le 1,000 least 6 month prior study entry Fasting triglyceride level great 150 mg/dl Body mass index ( BMI ) great 18.5 less 30 Uses barrier contraception Fasting triglyceride level great 1000 mg/dl BMI le 18.5 great 30 Taking diabetic medication HbA1c le 7.0 Use lipid lower medication 30 day prior study entry Unable exercise Tcell count le 100 Current medical condition make exercise unadvisable History coronary artery disease ( CAD ) Use dietary supplement ( within 30 day study entry ) may affect lipid level include , limited , follow : 1 . Omega3 fatty acid 2 . LCarnitine 3 . Soluble fiber supplement 4 . Guggul 5 . Garlic supplement 6 . Niacin great 25mg/d 7 . Oral liquid supplement Use steroid , hormone , testosterone ( without diagnosis hypogonadism , testosterone le 300 ng/dl ) Irregular period DepoProvera Hypo Hyperthyroidism Adrenal insufficiency Serum alanine aspartate aminotransferase level great 3 time upper limit normal Alcohol abuse Renal insufficiency ( creatinine level great 1.5 mg/dl ) Coumadin therapy Pregnancy Peptic ulcer disease Cholelithiasis History hyperuricemia History myositis rhabdomyolysis Known adverse reaction niacin fibrates Hepatitis C therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>